This Article Full Text Full Text (PDF) All Versions of this Article: 38/5/1519    most recent STROKEAHA.106.474262v1 Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Poole, K. E.S. Articles by Reeve, J. Search for Related Content PubMed PubMed Citation Articles by Poole, K. E.S. Articles by Reeve, J. Related Collections Other Stroke Treatment - Medical Exercise/exercise testing/rehabilitation Other Treatment Acute Stroke Syndromes

(Stroke. 2007;38:1519.)
© 2007 American Heart Association, Inc.

Original Contributions

A Single Infusion of Zoledronate Prevents Bone Loss After Stroke

Kenneth E.S. Poole, BM, PhD, MRCP; Nigel Loveridge, PhD; Collette M. Rose; Elizabeth A. Warburton, MA, DM, MRCP Jonathan Reeve, DM, DSc, FRCP

From Division of Bone Research (K.E.S.P., N.L., C.M.R., J.R.) and Department of Clinical Neurosciences (E.A.W.), Department of Medicine, University of Cambridge, Addenbrooke’s Hospital, Cambridge, England.

Correspondence to Kenneth E.S. Poole, Division of Bone Research Department of Medicine, University of Cambridge, Box 157, Addenbrooke’s Hospital, Cambridge, England, CB2 2QQ, UK. E-mail kp254{at}nhs.net

Background and Purpose— Stroke is a major risk factor for hip fracture. Patients with intermediate rather than severe or mild stroke deficits at the time of hospital discharge have the most fractures. This proof-of-concept study evaluated the efficacy of a single infusion of zoledronate, an intravenous bisphosphonate, in preserving hip bone density after stroke.

Methods— In a 1-year randomized, double-blind, placebo-controlled, clinical trial, 27 newly hemiplegic patients (6 females, 21 males) with acute stroke were assigned to receive 4 mg of the intravenous zoledronate (n=14) or placebo (n=13) within 35 days. Strict inclusion criteria were followed-up to ensure recruited patients were likely to have residual functional impairment. Both groups received calcium and vitamin D supplementation. The primary outcome measure was the change in bone mineral density (BMD; Lunar Prodigy) at the hemiplegic hip during the year of investigation.

Results— The treatment was generally well tolerated. Mean total hip BMD was unchanged in the hemiplegic hip of the zoledronate group (mean 0.0% change), whereas in the placebo group the total hip BMD changed by –5.5%, with the greatest bone loss observed in the trochanteric subregion (mean, –8.1%). On the unaffected side the mean change in total hip BMD was +1.0% with zoledronate versus a mean change of –2.7% without. Repeated measures ANOVA confirmed the significance of the differences between groups at both hips (hemiplegic, P<0.001; unaffected, P=0.002).

Conclusions— Stroke patients were protected from the deleterious effects of hemiplegia on hip bone density for at least 1 year after a single infusion of zoledronate.

Key Words: bone loss • hip fractures • randomized controlled trials • rehabilitation • stroke

This article has been cited by other articles:

				S. R. Heckbert, G. Li, S. R. Cummings, N. L. Smith, and B. M. Psaty Use of Alendronate and Risk of Incident Atrial Fibrillation in Women Arch Intern Med, April 28, 2008; 168(8): 826 - 831. [Abstract] [Full Text] [PDF]

				P.K. Myint, K.E.S. Poole, and E.A. Warburton Hip fractures after stroke and their prevention QJM, September 1, 2007; 100(9): 539 - 545. [Abstract] [Full Text] [PDF]

				R. N.J. de Nijs, A. A.A. Westgeest, K. E.S. Poole, S. Kaptoge, J. Reeve, R. Karam, J. Camm, M. McClung, M. A. Najib, I. Aziz, et al. Yearly zoledronic acid in postmenopausal osteoporosis. N. Engl. J. Med., August 16, 2007; 357(7): 711 - 712. [Full Text] [PDF]